A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease-Reference-Cited by-同舟云学术

A novel cognitive disease progression model for clinical trials in autosomal-dominant Alzheimer's disease

Published:2018-05-14 Issue:21 Volume:37 Page:3047-3055
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statistics in Medicine

Author:

Wang Guoqiao¹^ORCID,Berry Scott²,Xiong Chengjie¹,Hassenstab Jason³,Quintana Melanie²^ORCID,McDade Eric M.³,Delmar Paul⁴,Vestrucci Matteo⁴⁵,Sethuraman Gopalan⁶,Bateman Randall J.³,

Affiliation:

1. Division of Biostatistics; Washington University School of Medicine; St. Louis MO USA

2. Berry Consultants; Austin TX USA

3. Department of Neurology; Washington University School of Medicine; St. Louis MO USA

4. F. Hoffmann-La Roche Ltd.; Basel Switzerland

5. Department of Statistics and Data Sciences; University of Texas at Austin; Austin TX USA

6. Lilly Research Laboratories; Indianapolis IN USA

Funder

National Institutes of Health

National Institute on Aging

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/sim.7811/fullpdf

Reference27 articles.

1. Recent developments in Alzheimer's disease therapeutics;Rafii;BMC Med,2009

2. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014;Schneider;J Intern Med,2014

3. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline;Donohue;JAMA Neurol,2014

4. The DIAN-TU next generation Alzheimer's prevention trial: adaptive design and disease progression model;Bateman;Alzheimers Dement,2017

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Trials for Wolfram Syndrome Neurodegeneration: Novel Design, Endpoints, and Analysis Models;2024-09-11

2. 15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIAN;2024-08-09

3. New Horizons of Model Informed Drug Development in Rare Diseases Drug Development;Clinical Pharmacology & Therapeutics;2024-07-11

4. Statistical considerations when estimating time‐saving treatment effects in Alzheimer's disease clinical trials;Alzheimer's & Dementia;2024-06-21

5. Novel non‐linear models for clinical trial analysis with longitudinal data: A tutorial using SAS for both frequentist and Bayesian methods;Statistics in Medicine;2024-05-10